No impact on patient safety or on the product’s existing global regulatory filings

Dr Reddy's Laboratories has announced a setback in the distribution of their semaglutide products attributed to out-of-specification batches associated with an active ingredient…

Dr. Reddy's delays semaglutide supply due to ingredient issues, impacting shares but posing no safety risks.